RESUMO
Drug-drug interactions (DDIs) are of great concern in the treatment of cancer, especially when target therapies, such as tyrosine kinase inhibitors, are being used. Here, we report a case of probable DDI between erlotinib and amiodarone leading to severe neurotoxicity. Amiodarone inhibits P-glycoprotein (P-gp), for which erlotinib is a substrate. P-gp is an important drug transporter that is involved in limiting the blood-brain barrier penetration of erlotinib. Clinicians should be aware of emerging data characterizing the effect of the P-gp transport system on drug exposure and its potential for DDI.
Assuntos
Amiodarona/efeitos adversos , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma de Células Escamosas/tratamento farmacológico , Cloridrato de Erlotinib/efeitos adversos , Neoplasias Pulmonares/tratamento farmacológico , Membro 1 da Subfamília B de Cassetes de Ligação de ATP/antagonistas & inibidores , Amiodarona/uso terapêutico , Carcinoma Pulmonar de Células não Pequenas/radioterapia , Carcinoma de Células Escamosas/radioterapia , Progressão da Doença , Interações Medicamentosas , Cloridrato de Erlotinib/uso terapêutico , Humanos , Quimioterapia de Indução , Masculino , Pessoa de Meia-Idade , Paralisia/etiologia , Radioterapia , Suspensão de TratamentoRESUMO
BACKGROUND AND OBJECTIVE: We aimed to assess the population-based incidence and survival of primary Merkel cell carcinoma. MATERIAL AND METHOD: From January 1995 to December 2005, 19 patients diagnosed with primary Merkel cell carcinoma were recruited in the population-based Cancer Registry of Girona. RESULTS: The age-adjusted incidence was 1,3 per 10(6) person-year; higher in males (1,5) than in females (1,1). Cases occurred mostly in people older than 65 years (94,7%), especially involving the head (79%). CONCLUSIONS: To our knowledge, this study is the first to define the incidence and survival of Merkel cell carcinoma in Europe. The age-adjusted incidence of primary Merkel cell carcinoma in our area is similar than the age-adjusted incidence of the 2000 US standard population.
Assuntos
Carcinoma de Célula de Merkel/epidemiologia , Neoplasias Cutâneas/epidemiologia , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Incidência , Masculino , Pessoa de Meia-Idade , Taxa de Sobrevida , Fatores de TempoRESUMO
Fundamento y objetivo: Conocer la incidencia y supervivencia poblacional del carcinoma de células de Merkel. Material y método: De enero de 1995 a diciembre de 2005 se registraron un total de 19 casos de carcinoma primario de células de Merkel en la población cubierta por el Registro de Cáncer Poblacional de Girona. Resultados: La incidencia ajustada por edad a la población estándar mundial fue de 1,3 casos por 106 personas-año, siendo superior en varones (1,5) que en mujeres (1,1), con predominio de los casos en mayores de 65 años (94,7%). La región anatómica de la cabeza fue la localización afectada con mayor frecuencia (79%). Conclusiones: Se trata del primer trabajo, en nuestro conocimiento, que estima la incidencia y la supervivencia poblacional del carcinoma de células de Merkel en Europa. La incidencia observada en nuestra área es similar a la incidencia observada en EE. UU (AU)
Background and objective: We aimed to assess the population-based incidence and survival of primary Merkel cell carcinoma. Material and method: From January 1995 to December 2005, 19 patients diagnosed with primary Merkel cell carcinoma were recruited in the population-based Cancer Registry of Girona. Results: The age-adjusted incidence was 1,3 per 106 person-year; higher in males (1,5) than in females (1,1). Cases occurred mostly in people older than 65 years (94,7%), especially involving the head (79%). Conclusions: To our knowledge, this study is the first to define the incidence and survival of Merkel cell carcinoma in Europe. The age-adjusted incidence of primary Merkel cell carcinoma in our area is similar than the age-adjusted incidence of the 2000 US standard population (AU)
